NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected ...
Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced that it would be shedding 50% of its workforce by the end of June. Atara, a ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ('Atara Biotherapeutics, Inc.') ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically ...
HC Wainwright issued their FY2024 EPS estimates for Atara Biotherapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Burns forecasts that the ...
Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 40.50%, which has investors questioning if this is right time to ...